Acquisition strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough.
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies.
The two parties plan to collaborate to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development.
To focus on research and facility design to support Fujifilm’s goal to achieve net-zero carbon emissions by 2030 for its new $2 billion site in Holly Springs.
Lonza will assist ALSA Ventures’ portfolio companies with services supporting de-risking, early development and manufacturing of next-generation modalities.
Expansion will double the site’s existing lab footprint with an addition of 89,000 sq. ft equipped with state-of-the-art instrumentation and technologies.